665 related articles for article (PubMed ID: 15728164)
1. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
2. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
3. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
5. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
7. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
8. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.
Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR
Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666
[TBL] [Abstract][Full Text] [Related]
10. Symptom experience after discontinuing use of estrogen plus progestin.
Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
[TBL] [Abstract][Full Text] [Related]
11. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Utian WH; Shoupe D; Bachmann G; Pinkerton JV; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1065-79. PubMed ID: 11384629
[TBL] [Abstract][Full Text] [Related]
12. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
13. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
14. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
16. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
17. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
18. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
20. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
Archer DF; Dorin M; Lewis V; Schneider DL; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1080-7. PubMed ID: 11384630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]